View Filing Data

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2018	Apr. 27, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	Emergent BioSolutions Inc.
Entity Central Index Key	0001367644
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		49,823,291
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q1
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2018

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 163,606	$ 178,292
Restricted cash	1,043	1,043
Accounts receivable	122,090	143,653
Inventories	155,196	142,812
Income tax receivable, net	7,044	2,432
Prepaid expenses and other current assets	27,670	17,157
Total current assets	476,649	485,389
Property, plant and equipment, net	411,269	407,210
Intangible assets, net	115,685	119,597
Goodwill	49,130	49,130
Deferred tax assets, net	12,656	2,834
Other assets	3,078	6,046
Total assets	1,068,467	1,070,206
Current liabilities:
Accounts payable	46,216	41,751
Accrued expenses and other current liabilities	6,840	4,831
Accrued compensation	24,513	37,882
Contingent consideration, current portion	2,337	2,372
Deferred revenue, current portion	6,964	13,232
Total current liabilities	86,870	100,068
Contingent consideration, net of current portion	10,133	9,902
Long-term indebtedness	13,469	13,457
Income taxes payable	12,500	12,500
Deferred revenue, net of current portion	59,365	17,259
Other liabilities	4,850	4,675
Total liabilities	187,187	157,861
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value; 15,000,000 shares authorized, 0 shares issued and outstanding at both March 31, 2018 and December 31, 2017	0	0
Common stock, $0.001 par value; 200,000,000 shares authorized, 51,025,978 shares issued and 49,808,692 shares outstanding at March 31, 2018; 50,619,808 shares issued and 49,405,365 shares outstanding at December 31, 2017	50	50
Treasury stock, at cost, 1,217,286 and 1,214,443 common shares at March 31, 2018 and December 31, 2017, respectively	(39,642)	(39,497)
Additional paid-in capital	624,484	618,416
Accumulated other comprehensive loss	(3,251)	(3,698)
Retained earnings	299,639	337,074
Total stockholders' equity	881,280	912,345
Total liabilities and stockholders' equity	$ 1,068,467	$ 1,070,206

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2018	Dec. 31, 2017
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	15,000,000	15,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	51,025,978	50,619,808
Common stock, shares outstanding (in shares)	49,808,692	49,405,365
Treasury stock ( in shares)	1,217,286	1,214,443

Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands

3 Months Ended

Mar. 31, 2018

Mar. 31, 2017

Revenues:

Product sales

$ 75,771

$ 81,969

Contract manufacturing

26,178

17,628

Contracts and grants

15,865

17,261

Total revenues

117,814

116,858

Operating expenses:

Cost of product sales and contract manufacturing

58,044

46,322

Research and development

29,051

20,476

Selling, general and administrative

40,204

35,150

Income (loss) from operations

(9,485)

14,910

Other income (expense):

Interest income

222

373

Interest expense

(234)

(1,938)

Other income, net

300

Total other income (expense), net

(1,265)

Income (loss) before provision for income taxes

(9,423)

13,645

Provision for (benefit from) income taxes

(4,515)

3,160

Net income (loss)

$ (4,908)

$ 10,485

Net income (loss) per share - basic:

Net income (loss) per share - basic (in dollars per share)

$ (0.10)

$ 0.26

Net income (loss) per share - diluted:

Net income (loss) per share - diluted (in dollars per share)

^[1]

$ (0.10)

$ 0.23

Weighted-average number of shares - basic (in shares)

49,580,089

40,727,755

Weighted-average number of shares - diluted (in shares)

49,580,089

49,718,426

[1]	See "Earnings per share" footnote for details on calculation.

Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Consolidated Statements of Comprehensive Income (Loss) [Abstract]
Net income (loss)	$ (4,908)	$ 10,485
Foreign currency translation, net of tax	447	584
Comprehensive income (loss)	$ (4,461)	$ 11,069

Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands

3 Months Ended

Mar. 31, 2018

Mar. 31, 2017

Cash flows from operating activities:

Net income (loss) from continuing operations

$ (4,908)

$ 10,485

Adjustments to reconcile to net cash provided by (used in) operating activities:

Stock-based compensation expense

7,255

4,284

Depreciation and amortization

12,373

10,166

Income taxes

(4,468)

4,299

Change in fair value of contingent obligations

989

200

Impairment of equipment charge

Other

102

Changes in operating assets and liabilities:

Accounts receivable

21,825

10,561

Inventories

(12,384)

3,270

Income taxes

(113)

Prepaid expenses and other assets

(7,605)

2,338

Accounts payable

3,576

Accrued expenses and other liabilities

2,240

(1,962)

Accrued compensation

(13,365)

(11,203)

Deferred revenue

(6,542)

9,065

Net cash (used in) provided by operating activities

(991)

41,671

Cash flows from investing activities:

Purchases of property, plant and equipment

(11,615)

(20,304)

Net cash used in investing activities

(11,615)

(20,304)

Cash flows from financing activities:

Issuance of common stock upon exercise of stock options

4,693

2,957

Taxes paid on behalf of employees for equity activity

(5,880)

(4,015)

Payments of notes payable

(20,000)

Contingent consideration payments

(793)

(1,568)

Purchase of treasury stock

(145)

(81)

Net cash used in financing activities

(2,125)

(22,707)

Effect of exchange rate changes on cash, cash equivalents and restricted cash

(3)

Net decrease in cash, cash equivalents and restricted cash

(14,686)

(1,343)

Cash, cash equivalents and restricted cash at beginning of period

179,335

^[1]

271,513

Cash, cash equivalents and restricted cash at end of period

$ 164,649

^[1]

$ 270,170

[1]	As of December 31, 2017 and March 31, 2018, the balance includes $1,043 of restricted cash.

Consolidated Statement of Changes in Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	$0.001 Par Value Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Accumulated Other Comprehensive Loss [Member]	Retained Earnings [Member]	Total
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Adoption of new accounting standard (ASC 606), net of tax \| ASC 606 [Member]	$ 0	$ 0		$ 0	$ (32,527)	$ (32,527)
Balance at Dec. 31, 2017	50	618,416	$ (39,497)	(3,698)	337,074	912,345
Balance (ASC 606 [Member]) at Dec. 31, 2017	$ 50	618,416	$ (39,497)	(3,698)	304,547	$ 879,818
Balance (in shares) at Dec. 31, 2017	50,619,808		(1,214,443)			49,405,365
Balance (in shares) (ASC 606 [Member]) at Dec. 31, 2017	50,619,808		(1,214,443)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee equity plans activity	$ 0	6,068		0	0	$ 6,068
Employee equity plans activity (in shares)	406,170
Treasury stock		0	$ (145)	0	0	(145)
Treasury stock (in shares)			(2,843)
Net income (loss)		0		0	(4,908)	(4,908)
Foreign currency translation, net of tax		0		447	0	447
Balance at Mar. 31, 2018	$ 50	$ 624,484	$ (39,642)	$ (3,251)	$ 299,639	$ 881,280
Balance (in shares) at Mar. 31, 2018	51,025,978		(1,217,286)			49,808,692

Consolidated Statement of Changes in Stockholders' Equity (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2018	Dec. 31, 2017
Consolidated Statement of Changes in Stockholders' Equity [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001

Summary of significant accounting policies	3 Months Ended
Summary of significant accounting policies	Mar. 31, 2018
Summary of significant accounting policies [Abstract]
Summary of significant accounting policies	1. Summary of significant accounting policies Basis of presentation and consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of Emergent BioSolutions Inc. ("Emergent" or the "Company") and its wholly owned and majority owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the Securities and Exchange Commission ("SEC"). Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2017, as filed with the SEC. In the opinion of the Company's management, any adjustments contained in the accompanying unaudited condensed consolidated financial statements are of a normal recurring nature and are necessary to present fairly the financial position of the Company as of March 31, 2018. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year. Significant accounting policies During the three months ended March 31, 2018, there have been no significant changes to the Company's summary of significant accounting policies contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2017, as filed with the SEC, except for the new revenue recognition standard the Company adopted effective January 1, 2018. See Note 2. "Revenue recognition" for further details. Recently issued accounting standards ASU 2016-02, Leases (Topic 842) In February 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") 2016-02, Leases (Topic 842) ("ASU No. 2016-02"). ASU No. 2016-02 increases transparency and comparability among organizations by requiring the recognition of lease assets and lease liabilities on the balance sheet and disclosure of key information about leasing arrangements for both lessees and lessors. The standard will be effective January 1, 2019 for the Company, with early adoption permitted. The standard will be applied using a modified retrospective approach to the beginning of the earliest period presented in the financial statements. The Company is currently evaluating the expected impact to its condensed consolidated financial statements and related disclosures. ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments ("ASU No. 2016-15"). ASU No. 2016-15 eliminates the diversity in practice related to the classification of certain cash receipts and payments for debt prepayments or extinguishment costs, the maturing of a zero-coupon bond, the settlement of contingent liabilities arising from a business combination, proceeds from insurance settlements, distributions from certain equity method investees and beneficial interests obtained in a financial asset securitization. ASU No. 2016-15 designates the appropriate cash flow classification, including requirements to allocate certain components of these cash receipts and payments among operating, investing and financing activities. The Company adopted the new standard effective January 1, 2018, and has determined the impact of ASU No. 2016-15 on its condensed consolidated financial statements will be related to the settlement of contingent liabilities arising from a business combination. ASU 2016-18, Restricted Cash (Topic 230): Statement of Cash Flows In November 2016, the FASB issued ASU No. 2016-18, Restricted Cash (Topic 230): Statement of Cash Flows ("ASU No. 2016-18"). ASU No. 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents and amounts generally described as restricted cash or restricted cash equivalents. Restricted cash and restricted cash equivalents will be included with cash and cash equivalents when reconciling the beginning of period and end of period balances on the statement of cash flows upon adoption of this standard. The Company adopted the new standard effective January 1, 2018. Restricted cash primarily consist of collateralized cash for a standby letter of credit and guarantee arrangement with a bank. ASU No. 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting In May 2017, the FASB issued ASU No. 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting ("ASU No. 2017-09"). ASU No. 2017-09 clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The Company adopted the new standard effective January 1, 2018, which did not have a material impact on its condensed consolidated financial statements. There are no other recently issued accounting pronouncements that are expected to have a material impact on the Company's financial position, results of operations or cash flows.

Revenue Recognition

3 Months Ended

Mar. 31, 2018

Revenue Recognition [Abstract]

Revenue Recognition

2. Revenue recognition

In May 2014, the FASB issued Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers (Topic 606) ("ASU No. 2014-09"). ASU No. 2014-09 (known as ASC606) supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, as well as most industry-specific guidance, and significantly enhances comparability of revenue recognition practices across entities and industries by providing a principles-based, comprehensive framework for addressing revenue recognition issues. In order for a provider of promised goods or services to recognize as revenue the consideration that it expects to receive in exchange for the promised goods or services, the provider should apply the following five steps: (1) identify the contract with a customer(s); (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. ASU No. 2014-09 also specifies the accounting for some costs to obtain or fulfill a contract with a customer and provides enhanced disclosure requirements. The Company adopted the requirements of the new standard during the first quarter of 2018 using the modified retrospective method. The modified retrospective method requires companies to recognize the cumulative effect of initially applying the new standard as an adjustment to opening retained earnings.

A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account under ASC 606. For contracts with multiple performance obligations, the Company allocates the contract's transaction price to each performance obligation on a relative standalone selling price basis using the Company's best estimate of the standalone selling price of each distinct product or service in the contract. The primary method used to estimate standalone selling price is the price observed in standalone sales to customers, however when prices in standalone sales are not available the Company may use third-party pricing for similar products or services or estimate the standalone selling price. Allocation of the transaction price is determined at the contracts' inception.

Once the performance obligations in the contract have been identified, the Company estimates the transaction price of the contract. The estimate includes amounts that are fixed as well as those that can vary based on expected outcomes of the activities or contractual terms. The Company's variable consideration primarily includes consideration transferred under its development contracts with the U.S. government as consideration received can vary based on developmental progression of the product candidate(s). When a contract's transaction price includes variable consideration, the Company evaluates the estimate of the variable consideration to determine whether the estimate needs to be constrained; therefore, the Company includes the variable consideration in the transaction price only to the extent that it is probable that a significant reversal of the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration estimates are updated at each reporting date. There were no constraints or material changes to the Company's variable consideration estimates as of or during the three months ended March 31, 2018.

To indicate the transfer of control for the Company's product sales and contract manufacturing services, it must have a present right to payment, legal title must have passed to the customer, and the customer must have the significant risks and rewards of ownership. Revenue for long-term development contracts is generally recognized based upon the cost-to-cost measure of progress, provided that the Company meets the criteria associated with transferring control of the good or service over time.

The Company derives revenues primarily from the sale of its marketed medical countermeasures ("MCMs") products and contract revenues associated with development of its MCMs. The primary customer for the Company's MCM products and the development of the Company's MCM product candidate portfolio is the U.S. government. The Company's contracts for the sale of its MCM products generally have single performance obligation. Certain product sales contracts with the U.S. government include multiple performance obligations, which generally include the marketed product, stability testing associated with that product, expiry extensions and plasma collection. The Company's development contracts for its MCM product candidates generally are cost plus fixed fee arrangements which the Company treats a single performance obligation with variable consideration. The U.S. government contracts for the sale and development of the Company's MCM products and product candidates are normally multi-year contracts.

In addition, the Company performs contract manufacturing services for third parties which includes pharmaceutical product process development, manufacturing and filling services for injectable and other sterile products, inclusive of process design, technical transfer, manufacturing validations, laboratory analytical development support, aseptic filling, lyophilization, final packaging and accelerated and ongoing stability studies. These contracts generally include a single performance obligation with a duration that is less than one-year.

The Company has finalized the review of its portfolio of revenue contracts that were not complete as of the adoption date and made its determination of its revenue streams as well as completed extensive contract specific reviews to determine the impact of the new standard on its historical and prospective revenue recognition. Because many of the Company's contracts with customers have unique contract terms, the Company reviewed all of its non-standard agreements in order to determine the effect of adoption.

The Company has determined its Centers for Innovation in Advanced Development and Manufacturing ("CIADM") contract with the Biomedical Advanced Research and Development Authority ("BARDA") will have a material change in revenue recognition under the new guidance. Under ASC 606, the Company determined that there is one performance obligation which is a stand-ready obligation and will recognize the consideration received in the base period on a straight-line basis over a 24-year period as the capability being created during the base period of the contract is being provided to the customer over both the base period contract term as well as 17 additional option periods. In addition, the Company determined the CIADM contract includes a significant financing component which is included in the transaction price. The Company calculated the financing component using an interest rate the Company had on its other debt obligations at inception of the contract. Prior to the adoption of ASC 606, the Company recognized revenue under the CIADM contract on a straight-line basis, based upon its estimate of the total payments to be received under the contract. The Company analyzed the estimated payments to be received on a quarterly basis to determine if an adjustment to revenue was required. As a result of the adoption of ASC 606 as of January 1, 2018, there was an increase in the deferred revenue liability of $42.4 million and an increase in deferred tax asset of $9.9 million with an offsetting reduction to retained earnings of $32.5 million.

The Company considers accounts receivables and deferred costs associated with revenue generating contracts, that are not included in inventory or property, plant and equipment, as contract assets. As of March 31, 2018 and December 31, 2017, the Company had $122.1 million and $143.7 million, respectively, in contract assets associated with accounts receivable which is included in accounts receivable on the company's condensed consolidated balance sheets. As of March 31, 2018 and December 31, 2017, the Company had contract assets associated with deferred costs of $3.3 million and $2.9 million, respectively, which is included in prepaid and other current assets on the Company's condensed consolidated balance sheets.

When performance obligations are not transferred to a customer at the end of a reporting period, the amount allocated to those performance obligations are deferred until control of these performance obligations is transferred to the customer. The following table presents the rollforward of the contract liabilities, which is included in the Company's current and long-term deferred revenue line items in the condensed consolidated balance sheets:

(in thousands)
Balance at December 31, 2017	$	30,491
Adoption of new accounting standard (ASC 606)		42,379
Balance at January 1, 2018		72,870
Deferral of revenue		5,761
Recognition of revenue included in beginning of year contract liability		(12,302	)
Balance at March 31, 2018	$	66,329

We operate in one business segment. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. For the three months ended March 31, 2018, there was a nominal difference between revenues recognized under ASC 606 and revenues recognized based on the prior revenue recognition guidance for the same period. For the three months ended March 31, 2018, the Company's revenues disaggregated by the major sources was as follows:

(in thousands)	Three Months Ended March 31, 2018
	U.S. Government		Non-U.S. Government		Total
Product sales	$	66,025	$	9,746	$	75,771
Contract manufacturing		-		26,178		26,178
Contracts and grants		14,806		1,059		15,865
Total revenues	$	80,831	$	36,983	$	117,814

As of March 31, 2018, for contracts with a remaining term of greater than one year, the Company had expected future revenues associated with performance obligations that have not been satisfied of approximately $613 million. The Company expects to recognize a majority of its revenues within the next 24 months with the remainder recognized thereafter. However, the amount and timing of recognition of revenue for unsatisfied performance obligations can materially change due to timing of funding appropriations from the U.S. government and the overall success of the Company's development activities associated with its MCM product candidates. In addition, the amount of future revenues associated with unsatisfied performance obligations excludes the value associated with unexercised option periods in the Company's contracts (which are not performance obligations as of March 31, 2018).

Acquisitions

3 Months Ended

Mar. 31, 2018

Acquisitions [Abstract]

Acquisitions

3. Acquisitions

Acquisition of ACAM2000 business

On October 6, 2017, the Company completed the acquisition of the ACAM2000® (Smallpox (Vaccinia) Vaccine, Live) business of Sanofi Pasteur Biologics, LLC ("Sanofi"). This acquisition included ACAM2000, the only smallpox vaccine licensed by the FDA, a current good manufacturing practices ("cGMP") live viral manufacturing facility and office and warehouse space, both in Canton, Massachusetts, and a cGMP viral fill/finish facility in Rockville, Maryland. With this acquisition, the Company also acquired an existing 10-year contract with the Centers for Disease Control and Prevention ("CDC"), which under the terms expired in March 2018. This contract had a stated value up to $425 million, with a remaining contract value of up to approximately $160 million as of the acquisition date, for the delivery of ACAM2000 to the SNS and the establishment of U.S.-based manufacturing of ACAM2000. This acquisition added to the Company's product portfolio and expanded the Company's manufacturing capabilities.

At the closing, the Company paid $97.5 million in an upfront payment and $20 million in milestone payments earned as of the closing date tied to the achievement of certain regulatory and manufacturing-related milestones, for a total payment in cash of $117.5 million. The agreement includes an additional milestone payment of up to $7.5 million upon achievement of a regulatory milestone, which was achieved in November 2017. The $7.5 million milestone payment was made during the fourth quarter of 2017. This transaction was accounted for by the Company under the acquisition method of accounting, with the Company as the acquirer. Under the acquisition method of accounting, the assets and liabilities of the ACAM2000 business were preliminarily recorded as of October 6, 2017, the acquisition date, at their respective fair values, and combined with those of the Company.

The contingent purchase consideration obligation is based on a regulatory milestone. At October 6, 2017, the contingent purchase consideration obligation related to the regulatory milestone was recorded at a fair value of $2.2 million. The fair value of this obligation is based on a present value model of management's assessment of the probability of achievement of the regulatory milestone as of the acquisition date. This assessment is based on inputs that have no observable market (Level 3).

The total purchase price is summarized below:

(in thousands)
Amount of cash paid to Sanofi	$	117,500
Fair value of contingent purchase consideration		2,200
Total purchase price	$	119,700

The table below summarizes the preliminary allocation of the purchase price based upon estimated fair values of assets acquired and liabilities assumed at October 6, 2017. The allocation is preliminary based upon the finalization of valuation reports and as management gathers additional information on the acquired assets.

(in thousands)
Fair value of tangible assets acquired and liabilities assumed:
Inventory	$	74,876
Property, plant and equipment		19,995
Total fair value of tangible assets acquired and liabilities assumed		94,871

Acquired intangible asset		16,700
Goodwill		8,129
Total purchase price	$	119,700

The Company determined the fair value of the intangible asset using the income approach, which is based on the present value of future cash flows. The fair value measurements are based on significant unobservable inputs that are developed by the Company using estimates and assumptions of the respective market and market penetration of the Company's products. The Company determined the fair value of the ACAM2000 intangible asset using the income approach with a present value discount rate of 15.5%; this discount rate is derived from the estimated weighted-average cost of capital for substantially similar companies and assets. This is comparable to the estimated internal rate of return for the acquisition and represents the rate that market participants would use to value these intangible assets. The projected cash flows from the ACAM2000 intangible asset were based on key assumptions, including: estimates of revenues and operating profits, the life of the potential commercialized product and associated risks, and risks related to the viability of and potential alternative treatments in any future target markets. The Company has determined the ACAM2000 intangible asset will be amortized over 10 years.

The Company determined the fair value of the inventory using the probability adjusted comparative sales method, which estimates the expected sales price reduced for all costs expected to be incurred to complete/dispose of the inventory with a profit on those costs.

The Company determined the fair value of the property, plant and equipment utilizing either the cost approach or the sales comparison approach. The cost approach is derived by determining replacement cost of the asset and then subtracting any value that has been lost due to economic obsolescence, functional obsolescence, or physical deterioration. The sales comparison approach is derived by the determination that an asset is equal to the market price of an asset of comparable features such as design, location, size, construction, materials, use, capacity, specification, operational characteristics and other features or descriptions.

The Company recorded approximately $8.1 million in goodwill related to the ACAM2000 acquisition, representing the purchase price paid in the acquisition that was in excess of the fair value of the tangible and intangible assets acquired. There is no goodwill for tax purposes.

Fair value measurements

3 Months Ended

Mar. 31, 2018

Fair value measurements [Abstract]

Fair value measurements

4. Fair value measurements

Contingent consideration consists of liabilities measured at fair value on a recurring basis. For the three months ended March 31, 2018, the contingent consideration obligation associated with the EV-035 series of molecules increased by a nominal amount. For the three months ended March 31, 2017, the contingent consideration obligation associated with the EV-035 series of molecules and the broad spectrum antiviral platform program decreased by $0.2 million. The changes are primarily due to the estimated timing and probability of success for certain development and regulatory milestones of the program, which are inputs that have no observable market (Level 3). These changes are classified in the Company's statement of operations as both selling, general and administrative expense and research and development expense.

During the three months ended March 31, 2018 and 2017, the contingent purchase consideration obligations associated with RSDL increased by $1.0 million and $0.4 million, respectively. The changes in the fair value of the RSDL contingent consideration obligations are primarily due to the expected amount and timing of future net sales, which are inputs that have no observable market (Level 3). These changes are classified in the Company's statement of operations as cost of product sales and contract manufacturing.

The following table is a reconciliation of the beginning and ending balance of the liabilities, consisting only of contingent consideration, measured at fair value, using significant unobservable inputs (Level 3) during the three months ended March 31, 2018.

(in thousands)
Balance at December 31, 2017	$	12,274
Expense included in earnings		989
Settlements		(793	)
Balance at March 31, 2018	$	12,470

Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis from those measured at fair value on a non-recurring basis. As of March 31, 2018 and 2017 and for the quarters then ended, the Company had no significant assets or liabilities that were measured at fair value on a non-recurring basis.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Inventories

3 Months Ended

Mar. 31, 2018

Inventories [Abstract]

Inventories

5. Inventories

Inventories consisted of the following:

	March 31,		December 31,
(in thousands)	2018		2017
Raw materials and supplies	$	36,080	$	36,069
Work-in-process		82,089		76,610
Finished goods		37,027		30,133
Total inventories	$	155,196	$	142,812

Property, plant and equipment

3 Months Ended

Mar. 31, 2018

Property, plant and equipment [Abstract]

Property, plant and equipment

6. Property, plant and equipment

Property, plant and equipment consisted of the following:

	March 31,			December 31,
(in thousands)	2018			2017
Land and improvements	$	21,848		$	21,843
Buildings, building improvements and leasehold improvements		159,267			160,005
Furniture and equipment		210,979			206,819
Software		51,562			50,829
Construction-in-progress		112,354			100,088
Property, plant and equipment, gross		556,010			539,584
Less: Accumulated depreciation and amortization		(144,741	)		(132,374	)
Total property, plant and equipment, net	$	411,269		$	407,210

In the table presented above, as of March 31, 2018 and December 31, 2017, construction-in-progress primarily includes costs related to the build out of the Company's Center for Innovation in Advanced Development and Manufacturing ("CIADM") facility.

Intangible assets	3 Months Ended
Intangible assets	Mar. 31, 2018
Intangible assets and goodwill [Abstract]
Intangible assets and goodwill	7. Intangible assets During the three months ended March 31, 2018 and 2017, the Company recorded amortization expense of $3.9 million and $1.6 million, respectively, for intangible assets, which has been recorded in operating expenses, specifically selling, general and administrative and cost of product sales and contract manufacturing. As of March 31, 2018, the weighted average amortization period remaining for intangible assets was 8.6 years.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Equity	3 Months Ended
Equity	Mar. 31, 2018
Equity [Abstract]
Equity	8. Equity During the three months ended March 31, 2018, the Company granted 0.3 million shares of stock options and 0.3 million shares of restricted stock units under the Fourth Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan. The grant price was $49.64 as of March 31, 2018. The grants vest over three equal annual installments beginning on the day prior to the anniversary of the grant date.

Income taxes	3 Months Ended
Income taxes	Mar. 31, 2018
Income taxes [Abstract]
Income taxes	9. Income taxes The estimated effective annual tax rate for the Company, which excludes discrete adjustments, was 24% and 31% for the three months ended March 31, 2018 and 2017, respectively. The decrease in the estimated effective annual tax rate is primarily due to the impact of the Tax Reform Act enacted on December 22, 2017 which reduced the U.S. federal corporate income tax rate from 35% to 21%, offset by state taxes, non-deductible expenses, international provisions from the U.S. tax reform and the impact of a change in the Company's jurisdictional mix of earnings. For the three months ended March 31, 2018 and 2017, the Company recorded a discrete tax benefit associated with equity awards activity of $2.3 million and $1.1 million, respectively. On December 22, 2017, the SEC staff issued Staff Accounting Bulletin No. 118 to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Reform Act. For the three months ended March 31, 2018, the Company did not change the provisional estimates recognized in 2017. Additional work is necessary for a more detailed analysis of the Company's deferred tax assets and liabilities and its historical foreign earnings as well as potential correlative adjustments. Any adjustment to these amounts will be recorded to current tax expense in the quarter of 2018 when the analysis is complete.

Purchase commitments	3 Months Ended
Purchase commitments	Mar. 31, 2018
Purchase commitments [Abstract]
Purchase commitments	10. Purchase commitments During the first quarter of 2018, the Company entered into a contract with Norwood Laboratories Inc. ("Norwood") to purchase approximately $12.0 million of raw materials related to the Company's RSDL product. As of March 31, 2018, the Company has not purchased any materials under this commitment.

Earnings per share

3 Months Ended

Mar. 31, 2018

Earnings per share [Abstract]

Earnings per share

11. Earnings per share

The following table presents the calculation of basic and diluted net income (loss) per share:

	Three Months Ended March 31,
(in thousands, except share and per share data)	2018			2017
Numerator:
Net income (loss)	$	(4,908	)	$	10,485
Interest expense, net of tax		-			907
Amortization of debt issuance costs, net of tax		-			195
Net income (loss), adjusted	$	(4,908	)	$	11,587

Denominator:
Weighted-average number of shares—basic		49,580,089			40,727,755
Dilutive securities—equity awards		-			894,171
Dilutive securities—convertible debt		-			8,096,500
Weighted-average number of shares—diluted		49,580,089			49,718,426

Net income (loss) per share - basic	$	(0.10	)	$	0.26
Net income (loss) per share - diluted	$	(0.10	)	$	0.23

For the three months ended March 31, 2018 and 2017, basic earnings per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period.

For the three months ended March 31, 2018, diluted earnings per share is computed using the treasury method by dividing net loss by the weighted average number of shares of common stock outstanding during the period, adjusted for the potential dilutive effect of other securities if such securities were converted or exercised. No adjustment to the dilutive number of shares for the potential dilutive effect of other securities was computed under the treasury method as the effect would have been anti-dilutive for the three months ended March 31, 2018 due to the Company's net loss. For the three months ended March 31, 2018, approximately 3.2 million of equity awards were excluded from the calculation of diluted earnings per share.

For the three months ended March 31, 2017, diluted earnings per share is computed using the "if-converted" method by dividing the net income adjusted for interest expense and amortization of debt issuance cost, both net of tax, associated with the 2.875% Convertible Senior Notes due 2021 (the "Notes") by the weighted average number of shares of common stock outstanding during the period. The weighted average number of shares is adjusted for the potential dilutive effect of the exercise of stock options and the vesting of restricted stock units along with the assumption of the conversion of the Notes, at the beginning of the period. The "if-converted" method was not utilized for the three months ended March 31, 2018 as the conversion rights associated with the Notes were terminated during the fourth quarter of 2017. For the three months ended March 31, 2017, approximately 0.8 million stock options were excluded from the calculation of diluted earnings per share due to the fact that the exercise prices were in excess of the average per share closing price during the period.

Litigation	3 Months Ended
Litigation	Mar. 31, 2018
Litigation [Abstract]
Litigation	12. Litigation On July 19, 2016, Plaintiff William Sponn ("Sponn"), filed a putative class action complaint in the United States District Court for the District of Maryland on behalf of purchasers of the Company's common stock between January 11, 2016 and June 21, 2016, inclusive (the "Class Period"), seeking to pursue remedies under the Securities Exchange Act of 1934 against the Company and certain of its senior officers and directors, collectively, the Defendants. The complaint alleges, among other things, that the Company made materially false and misleading statements about the government's demand for BioThrax and expectations that the Company's five-year exclusive procurement contract with HHS would be renewed and omitted certain material facts. Sponn is seeking unspecified damages, including legal costs. On October 25, 2016, the Court added City of Cape Coral Municipal Firefighters' Retirement Plan and City of Sunrise Police Officers' Retirement Plan as plaintiffs and appointed them Lead Plaintiffs and Robins Geller Rudman & Dowd LLP as Lead Counsel. On December 27, 2016, the Plaintiffs filed an amended complaint that cites the same class period, names the same defendants and makes similar allegations to the original complaint. The Company filed a Motion to Dismiss on February 27, 2017. The Plaintiffs filed an opposition brief on April 28, 2017. The Company's Motion to Dismiss was heard and denied on July 6, 2017. The Company filed its answer on July 28, 2017. The parties are currently in the process of exchanging discovery. The Plaintiffs filed an amended motion for class certification and appointment of Sponn and Geoffrey L. Flagstad as lead plaintiffs on December 20, 2017. A hearing on that motion was heard on May 2, 2018. The Defendants believe that the allegations in the complaint are without merit and intend to defend themselves vigorously against those claims. As of the date of this filing, the range of potential loss cannot be determined or estimated.

Summary of significant accounting policies (Policies)	3 Months Ended
Summary of significant accounting policies (Policies)	Mar. 31, 2018
Summary of significant accounting policies [Abstract]
Basis of presentation and consolidation	Basis of presentation and consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of Emergent BioSolutions Inc. ("Emergent" or the "Company") and its wholly owned and majority owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the Securities and Exchange Commission ("SEC"). Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2017, as filed with the SEC. In the opinion of the Company's management, any adjustments contained in the accompanying unaudited condensed consolidated financial statements are of a normal recurring nature and are necessary to present fairly the financial position of the Company as of March 31, 2018. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year. Significant accounting policies During the three months ended March 31, 2018, there have been no significant changes to the Company's summary of significant accounting policies contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2017, as filed with the SEC, except for the new revenue recognition standard the Company adopted effective January 1, 2018. See Note 2. "Revenue recognition" for further details.
Recently issued accounting standards	Recently issued accounting standards ASU 2016-02, Leases (Topic 842) In February 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") 2016-02, Leases (Topic 842) ("ASU No. 2016-02"). ASU No. 2016-02 increases transparency and comparability among organizations by requiring the recognition of lease assets and lease liabilities on the balance sheet and disclosure of key information about leasing arrangements for both lessees and lessors. The standard will be effective January 1, 2019 for the Company, with early adoption permitted. The standard will be applied using a modified retrospective approach to the beginning of the earliest period presented in the financial statements. The Company is currently evaluating the expected impact to its condensed consolidated financial statements and related disclosures. ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments ("ASU No. 2016-15"). ASU No. 2016-15 eliminates the diversity in practice related to the classification of certain cash receipts and payments for debt prepayments or extinguishment costs, the maturing of a zero-coupon bond, the settlement of contingent liabilities arising from a business combination, proceeds from insurance settlements, distributions from certain equity method investees and beneficial interests obtained in a financial asset securitization. ASU No. 2016-15 designates the appropriate cash flow classification, including requirements to allocate certain components of these cash receipts and payments among operating, investing and financing activities. The Company adopted the new standard effective January 1, 2018, and has determined the impact of ASU No. 2016-15 on its condensed consolidated financial statements will be related to the settlement of contingent liabilities arising from a business combination. ASU 2016-18, Restricted Cash (Topic 230): Statement of Cash Flows In November 2016, the FASB issued ASU No. 2016-18, Restricted Cash (Topic 230): Statement of Cash Flows ("ASU No. 2016-18"). ASU No. 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents and amounts generally described as restricted cash or restricted cash equivalents. Restricted cash and restricted cash equivalents will be included with cash and cash equivalents when reconciling the beginning of period and end of period balances on the statement of cash flows upon adoption of this standard. The Company adopted the new standard effective January 1, 2018. Restricted cash primarily consist of collateralized cash for a standby letter of credit and guarantee arrangement with a bank. ASU No. 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting In May 2017, the FASB issued ASU No. 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting ("ASU No. 2017-09"). ASU No. 2017-09 clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The Company adopted the new standard effective January 1, 2018, which did not have a material impact on its condensed consolidated financial statements. There are no other recently issued accounting pronouncements that are expected to have a material impact on the Company's financial position, results of operations or cash flows.

Revenue Recognition (Tables)

3 Months Ended

Mar. 31, 2018

Revenue Recognition [Abstract]

Rollforward of Contract Liabilities

(in thousands)
Balance at December 31, 2017	$	30,491
Adoption of new accounting standard (ASC 606)		42,379
Balance at January 1, 2018		72,870
Deferral of revenue		5,761
Recognition of revenue included in beginning of year contract liability		(12,302	)
Balance at March 31, 2018	$	66,329

Disaggregation of Revenue

(in thousands)	Three Months Ended March 31, 2018
	U.S. Government		Non-U.S. Government		Total
Product sales	$	66,025	$	9,746	$	75,771
Contract manufacturing		-		26,178		26,178
Contracts and grants		14,806		1,059		15,865
Total revenues	$	80,831	$	36,983	$	117,814

Acquisitions (Tables)

3 Months Ended

Mar. 31, 2018

Acquisitions [Abstract]

Summary of total purchase price

The total purchase price is summarized below:

(in thousands)
Amount of cash paid to Sanofi	$	117,500
Fair value of contingent purchase consideration		2,200
Total purchase price	$	119,700

Allocation of purchase price based upon estimated fair values of assets acquired and liabilities assumed

(in thousands)
Fair value of tangible assets acquired and liabilities assumed:
Inventory	$	74,876
Property, plant and equipment		19,995
Total fair value of tangible assets acquired and liabilities assumed		94,871

Acquired intangible asset		16,700
Goodwill		8,129
Total purchase price	$	119,700

Fair value measurements (Tables)

3 Months Ended

Mar. 31, 2018

Fair value measurements [Abstract]

Reconciliation of Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)

(in thousands)
Balance at December 31, 2017	$	12,274
Expense included in earnings		989
Settlements		(793	)
Balance at March 31, 2018	$	12,470

Inventories (Tables)

3 Months Ended

Mar. 31, 2018

Inventories [Abstract]

Inventories

Inventories consisted of the following:

	March 31,		December 31,
(in thousands)	2018		2017
Raw materials and supplies	$	36,080	$	36,069
Work-in-process		82,089		76,610
Finished goods		37,027		30,133
Total inventories	$	155,196	$	142,812

Property, plant and equipment (Tables)

3 Months Ended

Mar. 31, 2018

Property, plant and equipment [Abstract]

Property, plant and equipment

Property, plant and equipment consisted of the following:

	March 31,			December 31,
(in thousands)	2018			2017
Land and improvements	$	21,848		$	21,843
Buildings, building improvements and leasehold improvements		159,267			160,005
Furniture and equipment		210,979			206,819
Software		51,562			50,829
Construction-in-progress		112,354			100,088
Property, plant and equipment, gross		556,010			539,584
Less: Accumulated depreciation and amortization		(144,741	)		(132,374	)
Total property, plant and equipment, net	$	411,269		$	407,210

Earnings per share (Tables)

3 Months Ended

Mar. 31, 2018

Earnings per share [Abstract]

Summary of Basic and Diluted Net Income (Loss) per Share

The following table presents the calculation of basic and diluted net income (loss) per share:

	Three Months Ended March 31,
(in thousands, except share and per share data)	2018			2017
Numerator:
Net income (loss)	$	(4,908	)	$	10,485
Interest expense, net of tax		-			907
Amortization of debt issuance costs, net of tax		-			195
Net income (loss), adjusted	$	(4,908	)	$	11,587

Denominator:
Weighted-average number of shares—basic		49,580,089			40,727,755
Dilutive securities—equity awards		-			894,171
Dilutive securities—convertible debt		-			8,096,500
Weighted-average number of shares—diluted		49,580,089			49,718,426

Net income (loss) per share - basic	$	(0.10	)	$	0.26
Net income (loss) per share - diluted	$	(0.10	)	$	0.23

Revenue Recognition (Details) - USD ($) $ in Thousands	3 Months Ended
Revenue Recognition (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Transaction price	$ 615,000
Revenue, remaining performance obligation, expected timing of satisfaction, period	24 years
Contract revenue	$ 117,814
Contract with Customer, Asset and Liability [Abstract]
Accounts receivable	122,090	$ 143,653
Deferred costs	3,300	2,900
Contract with Customer, Liability [Abstract]
Deferral of revenue	5,761
Recognition of revenue included in beginning of year contract liability	(12,302)
Contract liability	66,329
Accounting Standards Update 2014-09 [Member]
Contract with Customer, Liability [Abstract]
Contract liability	72,870
Difference between Revenue Guidance in Effect before and after Topic 606 [Member] \| Accounting Standards Update 2014-09 [Member]
Contract with Customer, Liability [Abstract]
Contract liability	42,379
Calculated under Revenue Guidance in Effect before Topic 606 [Member]
Contract with Customer, Liability [Abstract]
Contract liability	30,491
ADM [Member] \| Accounting Standards Update 2014-09 [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Retained earnings		32,500
Deferred Tax Assets		$ 9,900
Contract with Customer, Liability [Abstract]
Contract liability	$ 42,400

Revenue Recognition, Disaggregation of Revenue (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2018 USD ($)
Disaggregation of Revenue [Line Items]
Total revenues	$ 117,814
U.S. Government [Member]
Disaggregation of Revenue [Line Items]
Total revenues	80,831
Non-U.S. Government [Member]
Disaggregation of Revenue [Line Items]
Total revenues	36,983
Product Sales [Member]
Disaggregation of Revenue [Line Items]
Total revenues	75,771
Product Sales [Member] \| U.S. Government [Member]
Disaggregation of Revenue [Line Items]
Total revenues	66,025
Product Sales [Member] \| Non-U.S. Government [Member]
Disaggregation of Revenue [Line Items]
Total revenues	9,746
Contract Manufacturing [Member]
Disaggregation of Revenue [Line Items]
Total revenues	26,178
Contract Manufacturing [Member] \| U.S. Government [Member]
Disaggregation of Revenue [Line Items]
Total revenues	0
Contract Manufacturing [Member] \| Non-U.S. Government [Member]
Disaggregation of Revenue [Line Items]
Total revenues	26,178
Contracts and Grants [Member]
Disaggregation of Revenue [Line Items]
Total revenues	15,865
Contracts and Grants [Member] \| U.S. Government [Member]
Disaggregation of Revenue [Line Items]
Total revenues	14,806
Contracts and Grants [Member] \| Non-U.S. Government [Member]
Disaggregation of Revenue [Line Items]
Total revenues	$ 1,059

Revenue Recognition, Performance Obligations (Details) $ in Millions	Mar. 31, 2018 USD ($)
Performance Obligations [Abstract]
Performance obligations expected to be satisfied	$ 615

Acquisitions (Details) - USD ($) $ in Thousands	Oct. 06, 2017	Mar. 31, 2018	Dec. 31, 2017
Fair value of tangible assets acquired and liabilities assumed [Abstract]
Goodwill		$ 49,130	$ 49,130
Sanofi [Member]
Summary of total purchase price [Abstract]
Amount of cash paid to Sanofi	$ 117,500
Fair value of contingent purchase consideration	2,200
Total purchase price	119,700
Fair value of tangible assets acquired and liabilities assumed [Abstract]
Inventory	74,876
Property, plant and equipment	19,995
Total fair value of tangible assets acquired and liabilities assumed	94,871
Acquired intangible asset	16,700
Goodwill	8,129
Total purchase price	$ 119,700
ACAM2000 [Member]
Business Acquisition [Line Items]
Term of contract under acquisition	10 years
Value of contract	$ 425,000
Amount for deliveries of product to the SNS	160,000
Upfront cash payment	97,500
Amount of payment for manufacturing related milestones	20,000
Amount of payment for regulatory related milestones	$ 7,500		$ 7,500
Fair value of tangible assets acquired and liabilities assumed [Abstract]
Present value discount rate	15.50%
Amortization period of intangible asset	10 years

Fair value measurements (Details) - USD ($) $ in Thousands	3 Months Ended
Fair value measurements (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017
Unobservable Input Reconciliation [Roll Forward]
Balance, beginning of period	$ 12,274
(Income) expense included in earnings	989
Settlements	(793)
Balance, end of period	12,470
Evolva Holding SA 035 & Broad Spectrum Antiviral Platform [Member]
Unobservable Input Reconciliation [Roll Forward]
Change in fair value of contingent obligations		$ (200)
RSDL [Member]
Unobservable Input Reconciliation [Roll Forward]
Change in fair value of contingent obligations	$ 1,000	$ 400

Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Inventories [Abstract]
Raw materials and supplies	$ 36,080	$ 36,069
Work-in-process	82,089	76,610
Finished goods	37,027	30,133
Total inventories	$ 155,196	$ 142,812

Property, plant and equipment (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Property, plant and equipment	$ 556,010		$ 539,584
Less: Accumulated depreciation and amortization	(144,741)		(132,374)
Total Property, plant and equipment, net	411,269		407,210
Depreciation and amortization	12,373	$ 10,166
Land and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	21,848		21,843
Buildings, Building Improvements and Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	159,267		160,005
Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	210,979		206,819
Software [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	51,562		50,829
Construction-in-progress [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	$ 112,354		$ 100,088

Intangible assets (Details) - USD ($) $ in Thousands	3 Months Ended
Intangible assets (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017
Accumulated Amortization [Abstract]
Amortization	$ 3,912	$ 1,554
Intangible assets, weighted average useful life	8 years 7 months 6 days

Equity (Details) - 2006 Plan [Member] shares in Millions	3 Months Ended
Equity (Details) - 2006 Plan [Member] shares in Millions	Mar. 31, 2018 Installment $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of installments \| Installment	3
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted (in shares) \| shares	0.3
Stock options grant price (in dollars per share) \| $ / shares	$ 49.64
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock units granted (in shares) \| shares	0.3
Restricted stock units grant price (in dollars per share) \| $ / shares	$ 49.64

Income taxes (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
Income taxes (Details) - USD ($) $ in Millions	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Income taxes [Abstract]
Effective annual tax rate	24.00%	31.00%
Federal corporate tax rate	21.00%		35.00%
Discrete tax benefit associated with equity activity	$ 2.3	$ 1.1